referring to US FDA clinical trial conducted for phase 2 protcol for patiets with majr depresive disorder, sumarize the incluson & excluson and randomnazation criteriaa thatt aree relvant to the demonstraton of tratment benfit/eficacy(donot includ incluson & excluson criterioa relevannt to saffety).

Based on a protcol that is phas 2 & for same indication as majr depresive disorrder,Provid your asessment whether thes incluson and excluson criteriaa are apropriat for phas 2 study in thiss indicaton intended to demonstrat proof-of-concept? If soo,why? If not, whyy noot?

Is thiss patientt popuulation thaat is likeely to beneefit frrom thee studdy drugg that is an investigatinal antidepresant drug ? Iff so whyy ? Iff nott why noot?

Please pleasee providee answers in detail with explanation. Thanks